Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors
An erratum to this article was published (J Clin Endocrinol Metab, 17 Mar 2026 ↗)
Authors' conclusion
The predictive model proposed by the PANOMEN-3 group may be useful to guide the prognosis and therapy of PTs in the Spanish population since it offers a good accuracy to predict tumoral/biochemical recurrence and/or progression in operated and nonoperated patients.
Study context
- Population
- Patients with pituitary tumors followed ≥5 years; 814 operated, 329 on active surveillance or medical treatment; cases: recurrence/progression, controls253 cases · 890 controls · recurrence/progression 253 · controls 890
- Participants
- 1,143 patients
- Comparison
- PANOMEN-3 grades 0–3 for prediction of tumor recurrence/progression
- Outcome
- Validation of PANOMEN-3 classification for prediction of tumor recurrence/progression
- Follow-up
- Median 8.8 years (5-29.8)
Methodological detailsmulticenter, national
- Multicenter
- National
Main finding
As reported in the abstract
Diagnostic accuracy
75.6%
95% CI 0.716–0.796
Observational data: associations, not effects.
Further findings
Recurrence/progression rate by PANOMEN-3 grade — between Grade 3 and Grade 0 · across grades 0–3
P < 0.001
Most important model variables (Cox regression)
- Residual tumor, HR (P < .001)
- 2.20
- Hereditary syndrome, HR (P = .026)
- 5.15
- Active secretory status, HR (P = .021)
- 1.80
Time from PT diagnosis to recurrence
- Mean follow-up from diagnosis to recurrence (± 5.4 years)
- 7.2 years
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →